Affimed N.V. - Common Stock (AFMD)
0.1815
+0.00 (0.00%)
NASDAQ · Last Trade: May 29th, 10:26 AM EDT
Detailed Quote
Previous Close | 0.1815 |
---|---|
Open | - |
Bid | 0.1731 |
Ask | 0.1779 |
Day's Range | N/A - N/A |
52 Week Range | 0.0701 - 8.950 |
Volume | 0 |
Market Cap | 2.76M |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 59,255,825 |
Chart
About Affimed N.V. - Common Stock (AFMD)
Affimed is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy treatments for cancer. The company's proprietary platform harnesses the power of the immune system by designing next-generation bispecific antibodies that can specifically target and engage immune cells to attack and eliminate tumor cells. Affimed aims to create highly effective, targeted therapies that not only improve patient outcomes but also enhance the overall treatment experience, working on various candidates in its pipeline to advance the future of cancer care. Read More
News & Press Releases
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · May 19, 2025
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · May 19, 2025
Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · May 19, 2025
Via Benzinga · May 19, 2025
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · May 19, 2025
Via Benzinga · May 19, 2025
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · May 16, 2025
Let's have a look at what is happening on the US markets on Friday. Below you can find the most active stocks in today's session.
Via Chartmill · May 16, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · May 15, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · May 15, 2025
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · May 15, 2025
Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · May 14, 2025
MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company’s securities from The Nasdaq Stock Market (“Nasdaq”).
By Affimed N.V. · Via GlobeNewswire · May 14, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via Chartmill · May 13, 2025
Via Benzinga · May 13, 2025
MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.
By Affimed N.V. · Via GlobeNewswire · May 13, 2025
Via Benzinga · May 13, 2025
Via Benzinga · May 13, 2025
MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager (ICE®) AFM24, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) in a poster session at the 2025 Annual Meeting of the American Association for Cancer Research (AACR).
By Affimed N.V. · Via GlobeNewswire · April 29, 2025
MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025 in Chicago, Illinois. In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations.
By Affimed N.V. · Via GlobeNewswire · April 23, 2025
The company has been granted an initial period of 180 calendar days, or until October 13, 2025, to regain compliance with Nasdaq’s Minimum Bid Price Rule.
Via Stocktwits · April 21, 2025
MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).
By Affimed N.V. · Via GlobeNewswire · April 21, 2025